Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More

An all-important health ministry panel on February 25 backed approval for a throng of new medicines including Teijin Pharma’s osteoporosis treatment and JCR Pharmaceuticals’ sakigake -designated Hunter syndrome drug. If all goes well, they will be approved as early as...read more